Physician profile
Daniel Cartledge
NPI 1487836219
$14,136.30
in general payments reported to CMS, 2019-2025
48 companies · $2,585 in 2025
The $2,585 reported for 2025 was more than what 83% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,062 · 2020: $1,010 · 2021: $963 · 2022: $3,491 · 2023: $2,198 · 2024: $1,828 · 2025: $2,585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,446 · Travel and Lodging: $1,106 · Entertainment: $37.42 · Education: $21.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,445.80 |
| Travel and Lodging | $1,106.14 |
| Entertainment | $37.42 |
| Education | $21.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,299.58 | 2021-2025 | Vanta Adaptivestim, Synchromedii, Intellis Adaptivestim |
| Boston Scientific Corporation | $1,834.18 | 2022-2024 | Intracept |
| Foundation Fusion Solutions, LLC | $1,140.59 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $934.64 | 2019-2025 | Relistor |
| Curonix LLC | $825.83 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $824.00 | 2019-2025 | Belbuca, Xtampza |
| Nalu Medical, INC. | $763.47 | 2021-2025 | Nalu Neurostimulation System |
| Vertos Medical, INC. | $726.06 | 2021-2023 | Mild Device Kit |
| Abbott Laboratories | $715.72 | 2019-2024 | Eterna, Proclaim |
| Abbvie INC. | $648.50 | 2022-2025 | Qulipta, Ubrelvy, Botox |
| Nevro Corp. | $409.92 | 2019-2024 | Senza |
| Biodelivery Sciences International, INC. | $319.34 | 2019-2021 | |
| Medtronic USA, INC. | $299.54 | 2019-2020 | |
| Depuy Synthes Sales INC. | $213.57 | 2020-2025 | Orthovisc, Monovisc |
| Ibsa Pharma INC. | $212.11 | 2021-2025 | Tirosint, Tirosint, Licart |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Cartledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.